Supernus Pharmaceuticals, Inc. (SUPN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.52B
Last updated: Nov 17, 2026 at 11:06 AM ET
Supernus Pharmaceuticals, Inc. (SUPN) P/E Ratio & Valuation History
Supernus Pharmaceuticals (SUPN) trades at 12.7x trailing earnings and 2.0x sales. Its P/E of 12.7x is below its 5-year median of 17.4x. Its forward P/E is 20.2x. The median P/E across 11 similar companies is 10.7x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 37.1% lower over the next year. Its free cash flow yield is 1.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 12.7x |
| Forward P/E | 20.2x |
| Price to sales | 2.0x |
| Price to book | 1.6x |
| Price to FCF | 89.1x |
| EV/FCF | 79.5x |
| PEG | 1.5 |
| FCF yield | 1.1% |
Historical Medians
Against its 10-year medians, its P/E is 76.9% below 54.9x, its P/S is 84.3% below 12.7x and its P/B is 82.2% below 9.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 12.7x | 17.4x | 54.9x |
| P/S | 2.0x | 3.0x | 12.7x |
| P/B | 1.6x | 2.1x | 9.0x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 12.6x in 2023 to 158.1x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $49.70 | 17.5x | 3.9x | 2.7x |
| 2024 | $36.16 | 14.1x | 3.0x | 2.0x |
| 2023 | $28.94 | 12.6x | 2.6x | 1.7x |
| 2022 | $35.67 | 23.5x | 3.0x | 2.5x |
| 2021 | $145.80 | 148.8x | 13.4x | 9.5x |
| 2020 | $125.80 | 53.3x | 12.8x | 9.1x |
| 2019 | $118.60 | 56.2x | 15.9x | 10.7x |
| 2018 | $166.10 | 80.6x | 21.3x | 19.8x |
| 2017 | $199.25 | 158.1x | 33.9x | 39.9x |
| 2016 | $126.25 | 123.8x | 15.2x | 37.8x |
Frequently Asked Questions About SUPN
What is SUPN's forward P/E ratio?
Supernus Pharmaceuticals has a forward P/E ratio of 20.2x.
Is SUPN stock overvalued?
Its P/E of 12.7x compares with a median of 10.7x across 11 similar companies.
What is SUPN's price to sales ratio?
Supernus Pharmaceuticals has a price to sales ratio of 2.0x.
What is Supernus Pharmaceuticals's average P/E ratio over 5 years?
Supernus Pharmaceuticals's median P/E over the last 5 years is 17.4x, from 60 month-end values through Oct 2026.
What is SUPN's PEG ratio?
Supernus Pharmaceuticals has a PEG ratio of 1.5.
SUPN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors